MorphoSys AG — Investor Presentation 2007

Feb 13, 2007

MorphoSys AG Company Presentation | February 2007 © MorphoSys AG Page 4

MorphoSys AG Company Presentation | February 2007 © MorphoSys AG Page 16

Guidance 2006

In EUR millions	2006E*	2005
Revenues	Up to 52	33
Therapeutic Antibody Segment	34	29
Research Antibody Segment	18	4
Operating Expenses	46-49	28
EBIT	Up to 6	5
EBIT includes:
Investment in Product
& Technology Development	4	0.3
Restructuring
& Amortization of Acquired Intangibles	1.5	0.7

Profit & Loss Statement (Group)

In EUR millions	9-Month 2006	9-Month 2005
Revenues	39.0	23.8
Cost of Goods Sold	5.5	1.9
R&D Expenses	11.7	10.2
S,G&A Expenses	14.0	7.9
Total Operating Expenses	31.2	20.0
Profit from Operations	7.8	3.8
Non-Operating Expenses	0.5	0.1
Profit Before Taxes	7.4*	3.7
Income Tax Benefit/(Expense)	(1.2)	0.1
Net Profit	6.1*	3.9*
Earnings per Share (diluted) in EUR	0.93	0.67

* Differences due to rounding

MorphoSys AG Company Presentation | February 2007 © MorphoSys AG Page 20

Balance Sheet (Group)

In EUR millions	09/30/2006	12/31/2005
Assets
Cash, Cash Equivalents & Market. Securities	66.3*	53.6
Other Current Assets	11.5	4.9
Total Non-Current Assets	49.3	21.6
Total Assets	127.1	80.1
Liabilities
Total Current Liabilities	18.9	11.0
Total Non-Current Liabilities	9.4	5.1
Total Shareholders' Equity	98.7	64.0
Total Liabilities	127.1*	80.1